^
Association details:
| Biomarker: | CD38 positive |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Sarclisa (isatuximab-irfc) (CD38 inhibitor) + K-NK004 (CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Kiadis announces publication in Blood highlighting proof-of-concept to enhance potency of anti-CD38 antibodies with Kiadis’ K-NK004, recently licensed by Sanofi
Published date:
07/22/2020
Excerpt:
...CD38KO K-NK cells are resistant to killing by anti-CD38 antibodies, and demonstrates how CD38KO K-NK cells improve potency of anti-CD38 antibodies. This data drove Sanofi’s excitement to license KNK004 for combination with Sarclisa.
